Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

Rhea-AI Summary

Akebia Therapeutics (AKBA) announced three upcoming poster presentations at the 62nd European Renal Association Congress 2025, taking place June 4-7 in Vienna. The presentations will focus on clinical data for vadadustat, their treatment for CKD-related anemia. Key presentations include: a cardiovascular safety analysis of vadadustat in dialysis patients presented by Dr. Glenn Chertow, a study on vadadustat's combination with ferric citrate, and real-world data comparing HIF-PH inhibitors with ESAs in non-dialysis CKD patients from a Japanese database study.

News Market Reaction

+2.10%

1 alert

+2.10% News Effect

On the day this news was published, AKBA gained 2.10%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Vadadustat clinical data on display for nephrologists and healthcare providers

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it will present data at the 62^nd European Renal Association (ERA) Congress on June 4-7, 2025, both virtually and live in Vienna.

Akebia-supported presentations at ERA Congress 2025:

• A Win-Ratio Analysis of the Cardiovascular Safety of Vadadustat in Patients with CKD-Related Anemia Undergoing Dialysis
  Free Communication 15: Novel CKD Treatments Beyond the Pillars
  Abstract No. 3359
  Dr. Glenn Chertow to present on Friday, June 6 at 8:15 am CEST

• Vadadustat Combination with Ferric Citrate, Compared to Either Agent Alone, Protects Against Inflammation-Induced Anaemia and Anaemia-Induced by Chronic Kidney Disease
  E-Poster No. 2908

• Real-World Use of HIF-PH Inhibitors and ESAs in Non-Dialysis-Dependent CKD with Anemia: Insights from a Japanese Database study
  E-Poster No. 1325
  
  

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

FAQ

What data will Akebia Therapeutics (AKBA) present at ERA Congress 2025?

Akebia will present three studies: a cardiovascular safety analysis of vadadustat in dialysis patients, a combination study of vadadustat with ferric citrate, and real-world data comparing HIF-PH inhibitors with ESAs in non-dialysis CKD patients.

When and where is the ERA Congress 2025 where AKBA will present?

The 62nd European Renal Association Congress will be held from June 4-7, 2025, both virtually and live in Vienna.

Who will present the cardiovascular safety analysis for AKBA's vadadustat at ERA 2025?

Dr. Glenn Chertow will present the cardiovascular safety analysis on Friday, June 6 at 8:15 am CEST.

What is the purpose of Akebia Therapeutics' vadadustat presentations at ERA 2025?

The presentations aim to showcase clinical data on vadadustat for nephrologists and healthcare providers, focusing on its safety and efficacy in treating CKD-related anemia.